Ulcerative colitis is a chronic inflammatory bowel disease causing inflammation and ulcers in the colon and rectum. It typically follows a relapsing-remitting course with abdominal pain, diarrhea, rectal bleeding, and urgency.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07521904 |
Naturopathic Approaches to Ulcerative Colitis |
NOT_YET_RECRUITING | |
| NCT07520461 |
Microbiome-targeted Diet Therapy in Ulcerative Colitis |
NOT_YET_RECRUITING | NA |
| NCT07513181 |
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07501078 |
Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07494227 |
Development of the SC-IBD Self-Care Measurement Scale |
NOT_YET_RECRUITING | |
| NCT07463183 |
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) |
RECRUITING | PHASE2 |
| NCT07456566 |
Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease |
NOT_YET_RECRUITING | NA |
| NCT07428629 |
Piloting an Insomnia Treatment in Patients With Ulcerative Colitis |
RECRUITING | NA |
| NCT07421258 |
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting |
RECRUITING | |
| NCT07401680 |
Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population |
RECRUITING | PHASE1 |
